InsiderTrades.com logo
Banking failure dead ahead
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

HEM Insider Trading

Insider Ownership Percentage: 10.43%
Insider Buying (Last 12 Months): C$4,540.00
Insider Selling (Last 12 Months): C$23,719.48

Hemostemix Insider Trading History Chart

This chart shows the insider buying and selling history at Hemostemix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Hemostemix Share Price & Price History

Current Price: C$0.10
Price Change: ▲ Price Increase of +0.01 (11.11%)
As of 10/30/2024 01:03 PM ET

This chart shows the closing price history over time for HEM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Tim Sykes’ Urgent Trade Alert: “Make this move now”
From Timothy Sykes   |   Ad
Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.
Click here to see the surprising reason why

Hemostemix Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/18/2024Thomas SmeenkDirectorSell28,093C$0.08C$2,106.98
10/8/2024Thomas SmeenkDirectorSell332,500C$0.07C$21,612.5093
8/21/2024Thomas SmeenkDirectorBuy2,000C$0.04C$80.00
6/25/2024Thomas SmeenkDirectorBuy10,000C$0.04C$400.00
12/14/2023Thomas SmeenkDirectorBuy20,000C$0.07C$1,400.00
12/5/2023Thomas SmeenkDirectorBuy13,000C$0.07C$910.00
11/7/2023Thomas SmeenkDirectorBuy25,000C$0.07C$1,750.00
1/30/2023Thomas SmeenkDirectorBuy20,000C$0.22C$4,400.001,279,125
10/24/2022Thomas SmeenkDirectorBuy20,000C$0.15C$3,000.001,189,125
5/4/2022Thomas SmeenkDirectorBuy20,000C$0.30C$6,000.001,169,125
4/18/2022Thomas SmeenkDirectorSell300,000C$0.31C$93,210.001,149,125
See Full Table
Banking failure dead ahead
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Hemostemix (CVE:HEM)

Hemostemix logo
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Read More on Hemostemix

Today's Range

Now: C$0.10
Low: C$0.10
High: C$0.10

50 Day Range

MA: C$0.08
Low: C$0.05
High: C$0.11

52 Week Range

Now: C$0.10
Low: C$0.04
High: C$0.11

Volume

9,500 shs

Average Volume

99,960 shs

Market Capitalization

C$8.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

Who are the company insiders with the largest holdings of Hemostemix?

Hemostemix's top insider shareholders include:
  1. Thomas Smeenk (Director)
Learn More about top insider investors at Hemostemix.
This is treason
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.